Caerulein treatment of Parkinson's disease.
In view of evidence linking cholecystokinin-containing neurons with both dopamine system function and Parkinson's disease pathophysiology, the therapeutic effects of the cholecystokinin analog, caerulein, were evaluated in 10 parkinsonian patients stabilized on L-Dopa therapy. Despite substantially elevated plasma caerulein levels immediately following intramuscular injection of this peptide, no consistent change in neurologic status could be discerned. These negative results may be due to the relatively small amounts of caerulein entering the CNS at dose levels that do not induce gastrointestinal toxicity.
D000328:Adult; D000368:Aged; D002230:Carbidopa / Q000627:therapeutic use; D002108:Ceruletide / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*
D007980:Levodopa; D002108:Ceruletide; D002230:Carbidopa